{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006453","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.059828+00:00","generated_at":"2026-06-18T09:21:13.610430+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Enanta stockholders re-elect directors, approve equity plan amendment and say-on-pay","bullets":["Re-elected Bruce L.A. Carter and Jay R. Luly as Class I directors with 14.3M and 16.7M votes for.","Approved amendment to 2019 Equity Incentive Plan to increase authorized shares by 975,000.","Advisory say-on-pay vote approved with 16.2M votes for versus 1.4M against.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006453","json":"https://secwatch.observer/filing/0000950170-23-006453.json","markdown":"https://secwatch.observer/filing/0000950170-23-006453.md","text":"https://secwatch.observer/filing/0000950170-23-006453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/enta-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:21:13.610430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51ab371b49b64e308ea41bda8f978e787ef8de98","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Advisory vote on executive compensation (say-on-pay) at the 2023-03-02 meeting.","evidence_excerpt":"The stockholders approved the advisory vote on executive compensation, referred to as a \"say-on-pay\" vote.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-02"}],"fact_type":"shareholder_vote"},{"claim_id":"6955a1421b83c84fb6033f07a63a218e2e657e20","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Election of Two Class I Directors at the 2023-03-02 meeting.","evidence_excerpt":"The stockholders re-elected the following individuals as Class I directors of the Company: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Bruce L.A. Carter, Ph.D. 14,297,051 3,316,218 1,371,281 Jay R. Luly, Ph.D. 16,673,120 940,149 1,371,281","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-02"}],"fact_type":"shareholder_vote"},{"claim_id":"e565e0f8bed76bbb25a6909b8c9fa2a7f9e009f4","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Approve an Amendment to Our 2019 Equity Incentive Plan to increase the number of shares reserved by 975,000 shares at the 2023-03-02 meeting.","evidence_excerpt":"The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-02"}],"fact_type":"shareholder_vote"},{"claim_id":"f7ed3fe08df2d4571ce0cc5b5d2b07f929eb2baa","claim":"ENANTA PHARMACEUTICALS INC shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023 at the 2023-03-02 meeting.","evidence_excerpt":"The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023006453/0000950170-23-006453-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}